
Amarin Corporation (NASDAQ:AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovascular drug VAZKEPA (icosapent ethyl) across 59 countries in Europe.
What To Know: Under the terms of the deal, Amarin will receive $25 million in upfront cash and up to $150 million in additional milestone payments, tied to commercial net sales targets. Recordati will handle all commercialization activities for VAZKEPA in Europe.